ELAN
Price
$22.61
Change
+$0.23 (+1.03%)
Updated
Dec 26, 04:59 PM (EDT)
Capitalization
11.12B
61 days until earnings call
Intraday BUY SELL Signals
PAHC
Price
$38.17
Change
+$0.43 (+1.14%)
Updated
Dec 26, 04:59 PM (EDT)
Capitalization
1.53B
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAN vs PAHC

Header iconELAN vs PAHC Comparison
Open Charts ELAN vs PAHCBanner chart's image
Elanco Animal Health
Price$22.61
Change+$0.23 (+1.03%)
Volume$93.87K
Capitalization11.12B
Phibro Animal Health
Price$38.17
Change+$0.43 (+1.14%)
Volume$2.4K
Capitalization1.53B
ELAN vs PAHC Comparison Chart in %
ELAN
Daily Signal:
Gain/Loss:
PAHC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ELAN vs. PAHC commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Buy and PAHC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (ELAN: $22.38 vs. PAHC: $37.74)
Brand notoriety: ELAN: Notable vs. PAHC: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 48% vs. PAHC: 42%
Market capitalization -- ELAN: $11.12B vs. PAHC: $1.53B
ELAN [@Pharmaceuticals: Generic] is valued at $11.12B. PAHC’s [@Pharmaceuticals: Generic] market capitalization is $1.53B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 1 FA rating(s) are green whilePAHC’s FA Score has 1 green FA rating(s).

  • ELAN’s FA Score: 1 green, 4 red.
  • PAHC’s FA Score: 1 green, 4 red.
According to our system of comparison, PAHC is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 8 TA indicator(s) are bullish while PAHC’s TA Score has 3 bullish TA indicator(s).

  • ELAN’s TA Score: 8 bullish, 2 bearish.
  • PAHC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ELAN is a better buy in the short-term than PAHC.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а +1.36% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was -7.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +5.98%. For the same industry, the average monthly price growth was +12.50%, and the average quarterly price growth was +30.15%.

Reported Earning Dates

ELAN is expected to report earnings on Feb 25, 2026.

PAHC is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+5.98% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($11.1B) has a higher market cap than PAHC($1.53B). ELAN has higher P/E ratio than PAHC: ELAN (319.71) vs PAHC (22.60). ELAN (84.806) and PAHC (82.106) have similar YTD gains . ELAN has higher annual earnings (EBITDA): 840M vs. PAHC (181M). ELAN has more cash in the bank: 505M vs. PAHC (85.3M). PAHC has less debt than ELAN: PAHC (785M) vs ELAN (4.02B). ELAN has higher revenues than PAHC: ELAN (4.59B) vs PAHC (1.4B).
ELANPAHCELAN / PAHC
Capitalization11.1B1.53B725%
EBITDA840M181M464%
Gain YTD84.80682.106103%
P/E Ratio319.7122.601,415%
Revenue4.59B1.4B328%
Total Cash505M85.3M592%
Total Debt4.02B785M513%
FUNDAMENTALS RATINGS
ELAN vs PAHC: Fundamental Ratings
ELAN
PAHC
OUTLOOK RATING
1..100
1760
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
9040
PRICE GROWTH RATING
1..100
4045
P/E GROWTH RATING
1..100
295
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (27) in the Pharmaceuticals Major industry is significantly better than the same rating for ELAN (94) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew significantly faster than ELAN’s over the last 12 months.

PAHC's Profit vs Risk Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for ELAN (100) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew somewhat faster than ELAN’s over the last 12 months.

PAHC's SMR Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for ELAN (90) in the Agricultural Commodities Or Milling industry. This means that PAHC’s stock grew somewhat faster than ELAN’s over the last 12 months.

ELAN's Price Growth Rating (40) in the Agricultural Commodities Or Milling industry is in the same range as PAHC (45) in the Pharmaceuticals Major industry. This means that ELAN’s stock grew similarly to PAHC’s over the last 12 months.

ELAN's P/E Growth Rating (2) in the Agricultural Commodities Or Milling industry is significantly better than the same rating for PAHC (95) in the Pharmaceuticals Major industry. This means that ELAN’s stock grew significantly faster than PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANPAHC
RSI
ODDS (%)
Bullish Trend 3 days ago
74%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
55%
Bearish Trend 4 days ago
66%
MACD
ODDS (%)
Bullish Trend 3 days ago
64%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
70%
Advances
ODDS (%)
Bullish Trend 8 days ago
65%
Bullish Trend 16 days ago
74%
Declines
ODDS (%)
Bearish Trend 18 days ago
72%
Bearish Trend 8 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signal:
Gain/Loss:
PAHC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AIGOX35.520.13
+0.37%
Alger Growth & Income I-2
SSDIX37.960.13
+0.34%
DWS Small Cap Growth Inst
GLFOX18.130.04
+0.22%
Lazard Global Listed Infrastructure Open
OGICX40.390.04
+0.10%
Invesco Global Opportunities C
IVFCX4.54N/A
N/A
Federated Hermes Intl Strat Val Div C

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
+0.72%
VTRS - ELAN
48%
Loosely correlated
+1.83%
ZTS - ELAN
47%
Loosely correlated
+1.58%
PAHC - ELAN
40%
Loosely correlated
+0.94%
SNDL - ELAN
39%
Loosely correlated
-0.56%
AMRX - ELAN
37%
Loosely correlated
+0.23%
More

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with ELAN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+0.94%
ELAN - PAHC
41%
Loosely correlated
+0.72%
AMRX - PAHC
40%
Loosely correlated
+0.23%
ZTS - PAHC
37%
Loosely correlated
+1.58%
PBH - PAHC
37%
Loosely correlated
+0.18%
VTRS - PAHC
33%
Poorly correlated
+1.83%
More